WT/DS320/R Page 141
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Method for the Detection of Zeranol and SOP : ARO/442 Taleranol In
TITLE: Method for the detection of zeranol and S.O.P. : ARO/442 taleranol in meat and liver Page : 1 of 9 . Revision : 0 Date : 990715 1. INTRODUCTION 1.1 Summary This SOP describes a screening and confirmation method for the determination of resorcyclic acid lactones (RAL’s) in meat and liver samples of bovine origin. A procedure is described for the detection of a-zearalanol (zeranol) and b-zearalanol (taleranol) by a combination of solid phase extraction (SPE) and GC-MS. The method consist of, digestion of the meat sample using the enzyme protease and hydrolysis of the liver sample using suc d’Helix Pomatia, extraction of the RAL’s with tert-butylmethylether (TBME), purification using reversed-phase C18 cartridges. This method can also be used for the metabolites a-zearalenol, b-zearalenol, zearalanone and zearalenone. When doing so validation for these compounds is necessary. 1.2 Field of application The method is used to perform routine screening in meat and liver samples and has proven to be suitable for the analysis of a-zearalanol and b-zearalanol. The limit of detection is 0.5 mg/g based on the detection of the most abundant diagnostic ions namely m/z 433 and m/z 437 for the internal standard, with a response at the correct retention time exceeding the signal to noise ratio of 3. The method is validated according to SOP ARO/425 (1.3.3). 1.3 References 1.3.1. H.J. van Rossum et al, Multi residue analysis anabolic agents, SOP ARO/113, revision 4, 21 January 1997, RIVM. -
Studies of Fingerprint Matching Using the NIST Verification Test Bed (VTB)
Studies of Fingerprint Matching Using the NIST Verification Test Bed (VTB) Charles L. Wilson, Craig I. Watson, Michael D. Garris (from the National Institute of Standards & Technology) & Austin Hicklin (from Mitretek Systems) NISTIR 7020 ii TABLE OF CONTENTS Abstract........................................................................................................................................... 1 1. INTRODUCTION .................................................................................................................. 1 1.1 Brief History of Biometrics at NIST............................................................................... 2 1.2 Change in Focus as of 9-11............................................................................................. 2 1.2.1 USA PATRIOT Act Requirements......................................................................... 3 1.2.2 Border Security Act Requirements ......................................................................... 3 1.2.3 303A Report............................................................................................................ 3 1.3 Need for the VTB............................................................................................................4 1.4 Report Organization........................................................................................................ 5 2. VTB DESCRIPTION..............................................................................................................5 2.1 Hardware Description .................................................................................................... -
Étude in Vivo / in Vitro De L'effet De La Zéaralénone Sur L'expression De
Étude in vivo / in vitro de l’effet de la zéaralénone sur l’expression de transporteurs ABC majeurs lors d’une exposition gestationnelle ou néonatale Farah Koraichi To cite this version: Farah Koraichi. Étude in vivo / in vitro de l’effet de la zéaralénone sur l’expression de transporteurs ABC majeurs lors d’une exposition gestationnelle ou néonatale. Toxicologie. Université Claude Bernard - Lyon I, 2012. Français. NNT : 2012LYO10314. tel-01071280 HAL Id: tel-01071280 https://tel.archives-ouvertes.fr/tel-01071280 Submitted on 3 Oct 2014 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. N° d’ordre 314-2012 Année 2012 THESE DE L’UNIVERSITE DE LYON Délivrée par L’UNIVERSITE CLAUDE BERNARD LYON 1 ECOLE DOCTORALE INTERDISCIPLINAIRE SCIENCES-SANTE (EDISS) DIPLOME DE DOCTORAT (arrêté du 7 août 2006) soutenue publiquement le 20 décembre 2012 par Mlle Farah KORAÏCHI TITRE : ETUDE IN VIVO/IN VITRO DE L’EFFET DE LA ZEARALENONE SUR l’EXPRESSION DE TRANSPORTEURS ABC MAJEURS LORS D’UNE EXPOSITION GESTATIONNELLE OU NEONATALE Directeur de thèse: Sylvaine LECOEUR Co-directeur -
Annex D to the Report of the Panel to Be Found in Document WT/DS320/R
WORLD TRADE WT/DS320/R/Add.4 31 March 2008 ORGANIZATION (08-0902) Original: English UNITED STATES – CONTINUED SUSPENSION OF OBLIGATIONS IN THE EC – HORMONES DISPUTE Report of the Panel Addendum This addendum contains Annex D to the Report of the Panel to be found in document WT/DS320/R. The other annexes can be found in the following addenda: – Annex A: Add.1 – Annex B: Add.2 – Annex C: Add.3 – Annex E: Add.5 – Annex F: Add.6 – Annex G: Add.7 WT/DS320/R/Add.4 Page D-1 ANNEX D REPLIES OF THE SCIENTIFIC EXPERTS TO QUESTIONS POSED BY THE PANEL A. GENERAL DEFINITIONS 1. Please provide brief and basic definitions for the six hormones at issue (oestradiol-17β, progesterone, testosterone, trenbolone acetate, zeranol, and melengestrol acetate), indicating the source of the definition where applicable. Dr. Boisseau 1. Oestradiol-17β is the most active of the oestrogens hormone produced mainly by the developing follicle of the ovary in adult mammalian females but also by the adrenals and the testis. This 18-carbon steroid hormone is mainly administered as such or as benzoate ester alone (24 or 45 mg for cattle) or in combination (20 mg) with testosterone propionate (200 mg for heifers), progesterone (200 mg for heifers and steers) and trenbolone (200 mg and 40 mg oestradiol-17β for steers) by a subcutaneous implant to the base of the ear to improve body weight and feed conversion in cattle. The ear is discarded at slaughter. 2. Progesterone is a hormone produced primarily by the corpus luteum in the ovary of adult mammalian females. -
ACE Food Beverage Applications Guide
Food and Beverage Applications Guide Ultra-Inert Base Deactivated UHPLC / HPLC Columns Contents Application Index 1 Analyte Index 2 - 4 Application Notes 5 - 90 Send us your application and receive a free ACE column Send us your application on an ACE column and help extend our applications database. Your proven method will enable your chromatography colleagues to benefit and if we select your application for publication we’ll send you a FREE ACE analytical column of your choice. To submit your application e-mail us at: [email protected] ACE ® Food and Beverage Applications: Application Index Application Pages Application Pages Additives and intense sweeteners 5 Organic acids 2 47 Argicultural pesticides 6 Organic acids 3 48 Amino acids in peas 7 Organic acids 4 49 Amino acids and biogenic amines in wine and beer 8 Organophosphorus flame retardants in water by LC-MS/MS 50 Aminoglycosides in eggs 9 Organophosphorus isomer flame retardants in water 51 Annatto 10 Paraben preservatives 52 Anthocyanins from sambucus nigra (elderberry) 11 Perfluoro acids by LC-MS/MS 53 Appetite suppressants by LC-MS 12 Perfluoroalkyl substances by ion pairing LC-MS/MS 54 Arsenolipids from edible seaweed 13 Perfluorinated compounds in water by LC-MS/MS 55 Artificial colours (water soluble) 14 Pesticides (250 analytes) by LC-MS/MS 56 Artificial food colouring 15 Pesticides (47 analytes) by LC-MS/MS 60 Artificial sweeteners global method 16 Pesticides in water 61 Artificial sweeteners (stevia glycosides) 17 Phenolic compounds in ground water and landfill leachates -
Compound CAS
https://www.fermentek.com inhoud: Compound CAS# 100ìg 15 Acetoxyscirpenol 2623-22-5 1 mg 15-Acetyl-DON 88337-96-6 5mg 17-AAG 75747-14-7 10mg 17-DMAG 467214-20-6 25mg 3-Acetyl-DON 50722-38-8 50mg 7-Amino-Actinomycin D 7240-37-1 100mg A23187 Ca-Mg 52665-69-7 250mg A23187, 4-Bromo 76455-48-6 500mg A23187, free acid 52665-69-7 1gr Actinomycin D (≥ 97%) 50-76-0 5gr Actinomycin D (≥ 99%) 50-76-0 Aflatoxicol 29611-03-8 Aflatoxin B1 1162-65-8 Aflatoxin B2 7220-81-7 Aflatoxin G1 1165-39-5 Aflatoxin G2 7241-98-7 Aflatoxin M1 6795-23-9 Aflatoxin M2 6885-57-0 Alamethicin 27061-78-5 Alpha Zearalanol 26538-44-3 Alpha Zearalenol 36455-72-8 Altenuene 889101-41-1 Alternariol 641-38-3 Alternariol monomethyl Ether 26894-49-5 Altertoxin l 56258-32-3 Anisomycin 22862-76-6 Ansamitocin P3 66584-72-3 Antimycin A 1397-94-0 Aphidicolin 38966-21-1 Apicidin 183506-66-3 Ascomycin 11011-38-4 Aureothricin 574-95-8 Bafilomycin A1 88899-55-2 Bafilomycin B1 88899-56-3 Beauvericin 26048-05-5 Beta Zearalanol 42422-68-4 Beta Zearalenol 71030-11-0 Blasticidin S.HCl 9-3-3513 Borrelidin 7184-60-3 Brefeldin A 20350-15-6 Castanospermine 79831-76-8 Celastrol (tripterine) 34157-83-0 Cercosporin 35082-49-6 Cerulenin 17397-89-6 Chaetocin 28097-03-2 Chaetoglobosin A 50335-03-0 Chelerythrine Cl 3895-92-9 Chromomycin A3 7059-24-7 Citreoviridin 25425-12-1 Citrinin 518-75-2 Concanamycin A 80890-47-7 Cordycepin 73-03-3 Curvularin 10140-70-2 Cyclopamine 4449-51-8 Cyclopiazonic Acid 18172-33-3 Cytochalasin E 36011-19-5 Cytochalasin A 14110-64-6 Cytochalasin B 14930-96-2 Cytochalasin C 22144-76-9 -
Guide to Book Manufacturing Building Relationships for a Quality Experience
GUIDE TO BOOK MANUFACTURING BUILDING RELATIONSHIPS FOR A QUALITY EXPERIENCE Thomson Reuters, Guide to Book Manufacturing is a reference book intended for Thomson Reuters Core Publishing Solutions customers to give them a better understanding of the processes involved in creating, shipping, warehousing and distributing millions of books, pamphlets and newsletters produced annually. Project Lead Greg Groenjes Graphic Design Kelly Finco Vickie Jensen Janine Maxwell Contributing Writers Kelly Aune, Lori Clancy, Greg Groenjes, Brian Grunklee, Bob Holthe, Val Howard, Christine Hunter, Vickie Jensen, Sandi Krell, Linda Larson, Jerry Leyde, Kris Lundblad, Janine Maxwell, Walt Niemiec, John Reandeau, Nancy Roth, Jody Schmidt, Alex Siebenaler, Estelle Vruno Contributing Editor Christine Hunter Copy Editor Anne Kelley Conklin © 2018 Thomson Reuters. All rights reserved. July edition. TABLE OF CONTENTS Thomson Reuters Press Core Publishing Solutions Overview • Printing Background 7-1 • Thomson Reuters CPS 1-2 • Offset Presses 7-2 • Single-Color Web Press 7-2 Manufacturing Client Services • Web Press Components 7-3 (Planning & Scheduling) • Multi-Color Sheet-Fed Presses 7-6 • Service and Support 2-1 • Sheet-fed Press Description 7-6 • Roles and Responsibilities 2-2 • Sheet-fed Press Components 7-7 • Job Planning Process 2-3 • Color Printing 7-8 • Teamwork Is the Key to Success 2-5 • Colored Ink 7-8 • Considerations (Sheet-fed vs. Web) 7-9 Material Sourcing • Thomson Reuters Web Press Specifications 7-10 (Purchasing & Receiving) • Purchasing 3-1 Bindery -
The Thumbs Package
The thumbs package H.-Martin M¨unch <Martin.Muench at Uni-Bonn.de> 2014/03/09 v1.0q Abstract This LATEX package allows to create one or more customizable thumb index(es), providing a quick and easy reference method for large documents. It must be loaded after the page size has been set, when printing the document \shrink to page" should not be used, and a printer capable of printing up to the border of the sheet of paper is needed (or afterwards cutting the paper). Disclaimer for web links: The author is not responsible for any contents referred to in this work unless he has full knowledge of illegal contents. If any damage occurs by the use of information presented there, only the author of the respective pages might be liable, not the one who has referred to these pages. Save per page about 200 ml water, 2 g CO2 and 2 g wood: Therefore please print only if this is really necessary. 1 Contents 1 Introduction 4 2 Usage 4 2.1 Loading...........................................................4 2.2 Options...........................................................5 2.2.1 linefill........................................................5 2.2.2 minheight......................................................5 2.2.3 height........................................................5 2.2.4 width........................................................5 2.2.5 distance.......................................................5 2.2.6 topthumbmargin..................................................5 2.2.7 bottomthumbmargin................................................6 -
17-1595 ) Issued: November 26, 2018 DEPARTMENT of HEALTH & HUMAN ) SERVICES, NATIONAL INSTITUTES of ) HEALTH, Bethesda, MD, Employer ) ______)
United States Department of Labor Employees’ Compensation Appeals Board __________________________________________ ) B.A., Appellant ) ) and ) Docket No. 17-1595 ) Issued: November 26, 2018 DEPARTMENT OF HEALTH & HUMAN ) SERVICES, NATIONAL INSTITUTES OF ) HEALTH, Bethesda, MD, Employer ) __________________________________________ ) Appearances: Case Submitted on the Record Appellant, pro se Office of Solicitor, for the Director DECISION AND ORDER Before: CHRISTOPHER J. GODFREY, Chief Judge ALEC J. KOROMILAS, Alternate Judge VALERIE D. EVANS-HARRELL, Alternate Judge JURISDICTION On July 17, 2017 appellant filed a timely appeal from a March 17, 2017 merit decision of the Office of Workers’ Compensation Programs (OWCP).1 Pursuant to the Federal Employees’ Compensation Act2 (FECA) and 20 C.F.R. §§ 501.2(c) and 501.3, the Board has jurisdiction over the merits of this case. ISSUE The issue is whether appellant has met his burden of proof to establish permanent impairment of a scheduled member for schedule award purposes. 1 Appellant timely requested oral argument before the Board. By order dated December 18, 2017, the Board exercised its discretion and denied the request as the matter could be adequately addressed based on a review of the case record. Order Denying Request for Oral Argument, Docket No. 17-1595 (issued December 18, 2017). 2 5 U.S.C. § 8101 et seq. FACTUAL HISTORY On June 18, 1984 appellant, then a 34-year-old biologist, filed an occupational disease claim (Form CA-2) alleging that he developed a right hand condition that allegedly arose on or about May 2, 1984. He attributed his condition to repetitive use of laboratory equipment. OWCP accepted appellant’s claim for right hand tendinitis. -
Catalogue of Manuscripts in the Roth Collection’, Contributed by Cecil Roth Himself to the Alexander Marx Jubilee Volume (New York, 1950), Where It Forms Pp
Handlist 164 LEEDS UNIVERSITY LIBRARY Provisional handlist of manuscripts in the Roth Collection Introduction Dr Cecil Roth (1899-1970), the Jewish historian, was born on 5 March 1899 in Dalston, London, the youngest of the four sons of Joseph and Etty Roth. Educated at the City of London School, he saw active service in France in 1918 and then read history at Merton College, Oxford, obtaining a first class degree in modern history in 1922, and a DPhil in 1924; his thesis was published in 1925 as The Last Florentine Republic. In 1928 he married Irene Rosalind Davis. They had no children. Roth soon turned to Jewish studies, his interest from childhood, when he had a traditional religious education and learned Hebrew from the Cairo Genizah scholar Jacob Mann. He supported himself by freelance writing until in 1939 he received a specially created readership in post-biblical Jewish studies at the University of Oxford, where he taught until his retirement in 1964. He then settled in Israel and divided his last years between New York, where he was visiting professor at Queens’ College in City University and Stern College, and Jerusalem. He died in Jerusalem on 21 June 1970. Roth’s literary output was immense, ranging from definitive histories of the Jews both globally and in several particular countries, to bibliographical works, studies of painting, scholarly research, notably on the Dead Sea scrolls, and biographical works. But his crowning achievement was the editorship of the Encyclopaedia Judaica, which appeared in the year of his death. Throughout his life Roth collected both books and manuscripts, and art objects. -
03-Speranda.Vp:Corelventura
Acta Veterinaria (Beograd), Vol. 56, No. 2-3, 121-136, 2006. DOI: 10.2298/AVB0603121S UDK 619:636.4.087.7 HAEMATOLOGICAL AND BIOCHEMICAL PARAMETERS OF WEANED PIGLETS FED ON FODDER MIXTURE CONTAMINATED BY ZEARALENONE WITH ADDITION OF CLINOPTILOLITE [PERANDA MARCELA*, LIKER B**, [PERANDA T*, [ERI] V***, ANTUNOVI] Z*, GRABAREVI] @****, SEN^I] \*, GRGURI] D***** and STEINER Z* *Faculty of Agriculture, Osijek, Croatia; **Faculty of Agriculture, Zagreb, Croatia; ***Clinical Hospital Osijek, Croatia; ****Faculty of Veterinary Medicine, Zagreb, Croatia; *****Centar for Livestock Improvement, Osijek (Received 20. October 2005) The effect of zeolite clinoptilolite (CLIN) on some metabolic parameters in blood serum and haematological values in weaned piglets fed with increased levels of zearalenone (ZEN) was investigated over a 14-day period. The research involved four groups of weaned piglets aged 40 to 54 days. All groups were fed on fodder mixture for growing pigs containing 20% crude protein and 12.57 MJ ME/kg. The first control group (C1) received a concentrate mixture without added ZEN or mycotoxin adsorbent Min-a-Zel Plus®. The second control group (C2) was fed on fodder mixture containing 0.2% of modified clinoptilolite (Min-a-Zel Plus®; levels of zearalenone <5.1 ng/g). Piglets in the experimental group (E1) were fed on fodder mixture containing added zeralenone (3 mg/kg) (Sigma-Aldrich Co) and 0.2% of Min-a-Zel Plus® preparation. The second experimental group (E2) was fed on fodder mixture to which 3 mg/kg of zearalenone was added, but with no addition of Min-a-Zel Plus®. Oestrogenic effect of ZEN was evident in the sinergistic action with insulin which was manifested in an increased total protein level, lower level of glucose, triacylglycerols, serum iron, a higer level of cholesterol and higher aminotransaminase activity. -
Pharmaceutical Appendix to the Tariff Schedule 2
Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9